Sanofi (NYSE: SNY) reported Q1 EPS of EUR1.32, versus EUR1.17 reported last year. Revenue for the quarter came in at EUR8.81 billion, versus EUR7.84 billion reported last year.

Sanofi Chief Executive Officer, Olivier Brandicourt commented: "Sanofi had a good start to 2015. Our businesses provide a solid foundation for our new-product cycle. Sanofi's recent launches along with the ongoing regulatory reviews and planned submissions before year-end will drive future growth. At this important time for the company, my primary focus will be on maximizing the value of this innovative product portfolio and further establishing Sanofi as a leading biopharmaceutical company."

2015 financial guidance

• Sanofi continues to expect 2015 Business EPS(1) to be stable to slightly growing versus 2014 at constant average exchange rates, barring major unforeseen adverse events(5)
• In addition, the positive currency impact on 2015 full-year business EPS is estimated to be approximately +12%, under the assumption that exchange rates remain stable in the following three quarters at the average rates of March 2015

For earnings history and earnings-related data on Sanofi (SNY) click here.